The OftiM Newsreel
There are not enough seconds in the day for us to adequately cover all the incredible things that happen in the world of medical research - oncology or otherwise - or highlight some of the amazing patient stories we come across every day.
This page is devoted to highlighting patient stories, new trials and other assorted ramblings that may not get airtime on the show, but are still interesting, promising or inspiring.
OPAL - For when osimertinib is not enough…
Osimertinib has been nothing short of a game-changer for a segment of lung cancer sufferers. For the approximately 30% of patients with non-squamous non-small cell lung cancer (NSCLC) who carry an EGFR mutation, osimertinib has stretched out the average expected survival from months to years. To date, osimertinib has only been studied as a single agent. Until now…..